Citigroup
BBIO icon

Citigroup’s BridgeBio Pharma BBIO Stock Holding History

Citigroup’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4M Buy
+181,000
New +$13.1M 0.01% 1292
2025
Q1 		– Sell
-40,000
Closed -$1.1M – 5587
2024
Q4 		$1.1M Buy
+40,000
New +$1.03M ﹤0.01% 3294
2024
Q2 		– Sell
-29,900
Closed -$925K – 5578
2024
Q1 		$925K Hold
29,900
– – ﹤0.01% 3092
2023
Q4 		$1.21M Buy
29,900
+1,500
+5% +$45K ﹤0.01% 2666
2023
Q3 		$749K Buy
+28,400
New +$806K ﹤0.01% 2748
2022
Q4 		– Sell
-39,100
Closed -$389K – 5774
2022
Q3 		$389K Buy
+39,100
New +$406K ﹤0.01% 3415

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's BBIO Position: Q1 2026 in Review

Citigroup increased its BridgeBio Pharma (BBIO) stake by 6.6% in Q1 2026, buying an estimated $3.35M and bringing the position to 746,483 shares worth $55.4M. The position accounts for 0.02% of the portfolio, ranked #602.

Citigroup first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. The position peaked at $62.9M in Q4 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Citigroup held 746,483 shares of BridgeBio Pharma worth $55.4M as of Q1 2026.
  • Citigroup bought 46,232 BridgeBio Pharma shares in Q1 2026, an estimated $3.35M.
  • BridgeBio Pharma made up 0.02% of Citigroup's portfolio in Q1 2026, its #602 holding.
  • Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • Citigroup's BridgeBio Pharma position peaked at $62.9M in Q4 2023.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.